Shares of Intellia Therapeutics (NTLA) plunged 5.06% in premarket trading on Friday, following a downgrade by JPMorgan analysts. The firm cut its rating on the gene-editing company from Overweight to Neutral and significantly lowered its price target to $13, citing competitive pressures and challenges.
The premarket decline comes after Intellia reported fourth quarter and full-year 2024 results on Thursday, providing updates on its gene editing pipeline. While the company highlighted progress in key trials for its ATTR amyloidosis and hereditary angioedema (HAE) therapies, analysts raised concerns about the competitive landscape and Intellia's strategic restructuring efforts.
In particular, JPMorgan analysts cited potential competition from emerging TTR silencers and therapies for ATTR amyloidosis, which could challenge Intellia's lead candidate Nex-z in the market. They also noted risks around the company's focus on prioritized programs, following its decision to discontinue work on the NTLA-3001 program in favor of a second-generation approach.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。